Anacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis. Its product, KERYDIN (tavaborole) topical solution, approximately 5%, is an oxaborole antifungal approved by the United States Food and Drug Administration (FDA) for the topical treatment of onychomycosis of the toenails. It also has a pipeline of other internally discovered topical and systemic boron-based compounds in early-stages of research and development, which include AN3365. Its compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the treatment of human African trypanosomiasis.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:ANAC
- CUSIP: 03242010
- Web: www.anacor.com
Average Prices:- 50 Day Moving Avg: $93.23
- 200 Day Moving Avg: $81.52
- 52 Week Range: $52.00 - $156.93
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -162.62
- P/E Growth: 0.00
Profitability:- Net Margins: -92.08%
- Return on Equity: -133.71%
- Return on Assets: -38.09%
Misc:- Average Volume: 2.54 million shs.
Frequently Asked Questions for Anacor Pharmaceuticals (NASDAQ:ANAC)
What is Anacor Pharmaceuticals' stock symbol?
Anacor Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANAC."
How were Anacor Pharmaceuticals' earnings last quarter?
Anacor Pharmaceuticals Inc (NASDAQ:ANAC) announced its quarterly earnings data on Tuesday, May, 10th. The company reported ($0.36) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.35) by $0.01. The business earned $17.54 million during the quarter, compared to analysts' expectations of $19.53 million. Anacor Pharmaceuticals had a negative net margin of 92.08% and a negative return on equity of 133.71%. Anacor Pharmaceuticals's revenue for the quarter was up 14.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.30) EPS. View Anacor Pharmaceuticals' Earnings History.
Who are some of Anacor Pharmaceuticals' key competitors?
Some companies that are related to Anacor Pharmaceuticals include Incyte Corporation (INCY), Quintiles Transitional Holdings (Q), Alnylam Pharmaceuticals (ALNY), Alkermes PLC (ALKS), Seattle Genetics (SGEN), Qiagen N.V. (QGEN), Ionis Pharmaceuticals (IONS), Icon Plc (ICLR), Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), ACADIA Pharmaceuticals (ACAD), Bio-Techne Corp (TECH), PAREXEL International Corporation (PRXL), Puma Biotechnology (PBYI), FibroGen (FGEN) and Nektar Therapeutics (NKTR).
How do I buy Anacor Pharmaceuticals stock?
Shares of Anacor Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Anacor Pharmaceuticals' stock price today?
One share of Anacor Pharmaceuticals stock can currently be purchased for approximately $99.20.
MarketBeat Community Rating for Anacor Pharmaceuticals (NASDAQ ANAC)MarketBeat's community ratings are surveys of what our community members think about Anacor Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Anacor Pharmaceuticals (NASDAQ:ANAC)Earnings History by Quarter for Anacor Pharmaceuticals (NASDAQ ANAC)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/10/2016 | Q116 | ($0.35) | ($0.36) | $19.53 million | $17.54 million | View | Listen |  |
| 2/29/2016 | Q415 | ($0.30) | ($0.43) | $27.93 million | $21.20 million | View | Listen | |
| 11/3/2015 | Q315 | ($0.23) | ($0.37) | $25.60 million | $24.60 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.32) | ($0.30) | $18.55 million | $21.30 million | View | N/A | |
| 5/6/2015 | Q115 | ($0.47) | ($0.30) | $9.20 million | $15.26 million | View | N/A | |
| 3/12/2015 | Q414 | ($0.59) | ($0.21) | $4.74 million | $9.60 million | View | N/A | |
| 11/6/2014 | Q314 | ($0.65) | ($0.74) | $3.67 million | $3.96 million | View | N/A | |
| 8/7/2014 | Q214 | ($0.63) | ($0.58) | $3.03 million | $2.90 million | View | N/A | |
| 5/7/2014 | Q114 | ($0.39) | ($0.51) | $2.82 million | $4.15 million | View | N/A | |
| 3/13/2014 | Q413 | $3.01 | $3.01 | $2.85 million | $8.50 million | View | N/A | |
| 8/8/2013 | Q2 2013 | ($0.39) | ($0.36) | $2.60 million | $3.40 million | View | N/A | |
| 5/9/2013 | Q1 2013 | ($0.39) | ($0.42) | $2.57 million | $1.71 billion | View | N/A | |
| 3/14/2013 | Q4 2012 | ($0.45) | ($0.36) | $3.25 million | $3.28 million | View | N/A | |
| 11/7/2012 | Q312 | ($0.45) | ($0.46) | $3.18 million | $2.47 million | View | N/A | |
| 8/9/2012 | | ($0.45) | ($0.47) | | | View | N/A | |
| 5/10/2012 | | ($0.44) | ($0.48) | | | View | N/A | |
| 3/13/2012 | | ($0.35) | ($0.52) | | | View | N/A | |
| 11/10/2011 | | ($0.41) | ($0.16) | | | View | N/A | |
| 8/11/2011 | | ($0.45) | ($0.54) | | | View | N/A | |
| 5/5/2011 | | ($0.31) | ($0.49) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Anacor Pharmaceuticals (NASDAQ:ANAC)2017 EPS Consensus Estimate: $2.98
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.53) | ($0.53) | ($0.53) |
| Q2 2017 | 1 | $0.52 | $0.52 | $0.52 |
| Q3 2017 | 1 | $1.32 | $1.32 | $1.32 |
| Q4 2017 | 1 | $1.67 | $1.67 | $1.67 |
(Data provided by Zacks Investment Research)
Dividend History for Anacor Pharmaceuticals (NASDAQ:ANAC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Anacor Pharmaceuticals (NASDAQ:ANAC)Insider Trades by Quarter for Anacor Pharmaceuticals (NASDAQ:ANAC)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/1/2016 | Graeme Bell | CFO | Sell | 751 | $99.28 | $74,559.28 | |
| 5/23/2016 | Keith R Leonard | Director | Sell | 9,000 | $99.70 | $897,300.00 | |
| 5/16/2016 | Anders D Hove | Director | Sell | 353,881 | $99.59 | $35,243,008.79 | |
| 4/29/2016 | Ryan T Sullivan | EVP | Sell | 3,125 | $66.33 | $207,281.25 | |
| 4/8/2016 | Anders D Hove | Director | Sell | 229,301 | $71.10 | $16,303,301.10 | |
| 3/22/2016 | Paul L Berns | CEO | Sell | 37,500 | $60.31 | $2,261,625.00 | |
| 1/19/2016 | Vincent P. Ippolito | EVP | Sell | 20,000 | $95.41 | $1,908,200.00 | |
| 1/15/2016 | Lee Zane | SVP | Sell | 1,466 | $89.57 | $131,309.62 | |
| 1/4/2016 | Paul L. Berns | CEO | Sell | 2,533 | $112.35 | $284,582.55 | |
| 1/4/2016 | Ryan T. Sullivan | VP | Sell | 733 | $111.78 | $81,934.74 | |
| 1/4/2016 | Vincent P. Ippolito | EVP | Sell | 855 | $112.28 | $95,999.40 | |
| 12/11/2015 | Paul L. Berns | CEO | Sell | 20,000 | $117.26 | $2,345,200.00 | |
| 12/10/2015 | Ryan T. Sullivan | VP | Sell | 10,000 | $110.41 | $1,104,100.00 | |
| 9/15/2015 | Lee Zane | SVP | Sell | 14,000 | $139.84 | $1,957,760.00 | |
| 9/15/2015 | Paul L. Berns | CEO | Sell | 20,000 | $139.83 | $2,796,600.00 | |
| 8/13/2015 | Paul L Berns | CEO | Sell | 20,000 | $138.69 | $2,773,800.00 | |
| 6/15/2015 | Lee Zane | SVP | Sell | 12,000 | $69.05 | $828,600.00 | |
| 5/15/2015 | Jacob J Plattner | VP | Sell | 8,920 | $63.73 | $568,471.60 | |
| 5/14/2015 | Carmen R Rodriguez | VP | Sell | 61,942 | $62.73 | $3,885,621.66 | |
| 4/29/2015 | Ryan T Sullivan | VP | Sell | 3,125 | $53.61 | $167,531.25 | |
| 4/27/2015 | Paul L Berns | CEO | Sell | 50,000 | $63.64 | $3,182,000.00 | |
| 4/15/2015 | Jacob J Plattner | VP | Sell | 8,920 | $62.81 | $560,265.20 | |
| 3/23/2015 | Geoffrey M Parker | CFO | Buy | 3,000 | $52.43 | $157,290.00 | |
| 3/16/2015 | Jacob J Plattner | VP | Sell | 8,920 | $55.60 | $495,952.00 | |
| 3/16/2015 | Lee Zane | SVP | Sell | 12,000 | $56.44 | $677,280.00 | |
| 3/4/2015 | Sanjay Chanda | SVP | Sell | 5,000 | $45.00 | $225,000.00 | |
| 3/3/2015 | Vincent P Ippolito | EVP | Sell | 9,000 | $43.88 | $394,920.00 | |
| 3/2/2015 | Jacob J Plattner | VP | Sell | 6,875 | $44.02 | $302,637.50 | |
| 3/2/2015 | Kirk R Maples | SVP | Sell | 600 | $43.95 | $26,370.00 | |
| 1/2/2015 | Jacob J Plattner | VP | Sell | 6,875 | $32.09 | $220,618.75 | |
| 12/26/2014 | Paul L Berns | CEO | Sell | 25,000 | $30.82 | $770,500.00 | |
| 12/12/2014 | Lucy Shapiro | Director | Sell | 289,685 | $35.11 | $10,170,840.35 | |
| 12/11/2014 | Lee Zane | SVP | Sell | 4,900 | $36.09 | $176,841.00 | |
| 12/9/2014 | Kirk R Maples | SVP | Sell | 60,000 | $36.52 | $2,191,200.00 | |
| 12/1/2014 | Jacob J Plattner | VP | Sell | 6,875 | $33.34 | $229,212.50 | |
| 12/1/2014 | Kirk R Maples | SVP | Sell | 600 | $33.38 | $20,028.00 | |
| 11/26/2014 | Sanjay Chanda | SVP | Sell | 5,000 | $35.00 | $175,000.00 | |
| 11/3/2014 | Jacob J Plattner | VP | Sell | 6,875 | $29.32 | $201,575.00 | |
| 10/1/2014 | Jacob J Plattner | VP | Sell | 6,875 | $24.47 | $168,231.25 | |
| 9/26/2014 | Anders D Hove | Director | Sell | 20,000 | $25.00 | $500,000.00 | |
| 9/19/2014 | Anders D Hove | Director | Sell | 740,000 | $24.87 | $18,403,800.00 | |
| 9/16/2014 | Anders D Hove | Director | Sell | 90,000 | $24.99 | $2,249,100.00 | |
| 9/10/2014 | Sanjay Chanda | SVP | Sell | 10,000 | $24.25 | $242,500.00 | |
| 9/8/2014 | Geoffrey M Parker | CFO | Buy | 6,590 | $21.82 | $143,793.80 | |
| 8/27/2014 | Mark Leschly | Director | Sell | 13,067 | $22.50 | $294,007.50 | |
| 5/20/2014 | Kirk Maples | SVP | Sell | 1,500 | $14.15 | $21,225.00 | |
| 4/21/2014 | Kirk Maples | SVP | Sell | 1,500 | $15.60 | $23,400.00 | |
| 3/24/2014 | Geoffrey Parker | CFO | Buy | 5,000 | $20.11 | $100,550.00 | |
| 3/21/2014 | Lucy Shapiro | Director | Sell | 80,000 | $21.14 | $1,691,200.00 | |
| 3/20/2014 | Kirk Maples | SVP | Sell | 3,000 | $22.39 | $67,170.00 | |
| 3/18/2014 | Geoffrey Parker | CFO | Buy | 2,410 | $22.60 | $54,466.00 | |
| 3/5/2014 | David Perry | CEO | Sell | 65,000 | $20.22 | $1,314,300.00 | |
| 2/20/2014 | Kirk Maples | SVP | Sell | 3,000 | $19.33 | $57,990.00 | |
| 2/5/2014 | David Perry | CEO | Sell | 15,000 | $17.00 | $255,000.00 | |
| 1/21/2014 | Kirk Maples | SVP | Sell | 3,000 | $20.27 | $60,810.00 | |
| 1/9/2014 | David Perry | CEO | Sell | 65,000 | $16.32 | $1,060,800.00 | |
| 12/9/2013 | David Perry | CEO | Sell | 40,328 | $16.23 | $654,523.44 | |
| 11/26/2013 | Geoffrey Parker | CFO | Buy | 10,000 | $13.40 | $134,000.00 | |
| 11/25/2013 | Geoffrey Parker | CFO | Buy | 10,000 | $12.85 | $128,500.00 | |
| 8/14/2013 | Kirk Maples | SVP | Sell | 1,052 | $9.71 | $10,214.92 | |
| 8/13/2013 | Geoffrey Parker | CFO | Buy | 50,000 | $8.34 | $417,000.00 | |
| 6/19/2013 | Geoffrey M Parker | CFO | Buy | 23,046 | $5.20 | $119,839.20 | |
| 6/18/2013 | Geoffrey M Parker | CFO | Buy | 20,000 | $5.22 | $104,400.00 | |
| 6/14/2013 | Kirk R Maples | SVP | Sell | 5,600 | $5.39 | $30,184.00 | |
| 11/26/2012 | Kirk R Maples | SVP | Sell | 3,000 | $5.22 | $15,660.00 | |
| 11/1/2012 | Kirk R Maples | SVP | Sell | 3,000 | $5.81 | $17,430.00 | |
| 10/5/2012 | Lucy Shapiro | Director | Sell | 30,000 | $6.67 | $200,100.00 | |
| 8/22/2012 | Geoffrey M Parker | CFO | Buy | 5,000 | $6.19 | $30,950.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Anacor Pharmaceuticals (NASDAQ:ANAC)
Latest Headlines for Anacor Pharmaceuticals (NASDAQ:ANAC)
| Source: |
|
Anacor Pharmaceuticals (ANAC) Chart for Sunday, September, 24, 2017
